The purpose of the study is to evaluate the safety and tolerability of multiple doses of
LLF580 administered subcutaneously over 3 months in obese subjects. In addition, the study
will also determine early efficacy signals in various metabolic diseases associated with
elevated triglycerides and/or obesity.